Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund”. A copy of the letter is available to download here. The small caps’ earnings are reaccelerating in 2025, as the firm forecasted a year ago. The market also experienced a low-quality rally within the small-cap space. Against this backdrop, the Small Cap Growth Fund underperformed the Russell 2000 Growth Index benchmark in the quarter, returning 0.51% vs. 1.22% for the benchmark. Heading into 2026, there are many reasons to feel positive about the economy, earnings growth, and the stock market. Please review the Fund’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, Loomis Sayles Small Cap Growth Fund highlighted Wave Life Sciences Ltd. (NASDAQ:WVE) as one of its leading contributors. Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage biotechnology company focused on developing RNA-targeted therapies. On March 24, 2026, Wave Life Sciences Ltd. (NASDAQ:WVE) stock closed at $11.63 per share. One-month return of Wave Life Sciences Ltd. (NASDAQ:WVE) was -20.01%, and its shares gained 24.75% over the past 52 weeks. Wave Life Sciences Ltd. (NASDAQ:WVE) has a market capitalization of $2.19 billion.
Loomis Sayles Small Cap Growth Fund stated the following regarding Wave Life Sciences Ltd. (NASDAQ:WVE) in its fourth quarter 2025 investor letter:
“Establishment Labs Holdings, Wave Life Sciences Ltd. (NASDAQ:WVE) and MACOM Technology Solutions Holdings were the top individual contributors overall. Wave Life Sciences is a biotech company focused on utilizing RNA technologies to treat various conditions. During the quarter, the company published its first data for a novel obesity target showing a reduction in fat mass while preserving muscle mass and the stock reacted positively as a result.”
Wave Life Sciences Ltd. (NASDAQ:WVE) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 45 hedge fund portfolios held Wave Life Sciences Ltd. (NASDAQ:WVE) at the end of the fourth quarter, up from 38 in the previous quarter. While we acknowledge the risk and potential of Wave Life Sciences Ltd. (NASDAQ:WVE) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Wave Life Sciences Ltd. (NASDAQ:WVE) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Wave Life Sciences Ltd. (NASDAQ:WVE) and shared a bullish thesis on the company. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
